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Background:  Serum adiponectin is cardioprotective against incident coronary artery disease (CAD). However, in patients with existing CAD, higher 
adiponectin levels are paradoxically associated with worse ischemia. We sought to further investigate this apparent paradox by evaluating the 
relationship between adiponectin, heart failure and mortality in patients with existing CAD.
Methods:  We measured total serum adiponectin concentrations and baseline cardiac disease severity (inducible ischemia, left ventricular 
ejection fraction and diastolic dysfunction by echocardiography) in 981 outpatients with stable CAD who were recruited for the Heart and Soul Study 
between September 2000 and December 2002. Subsequent heart failure hospitalizations and death were determined by review of medical records, 
coroner reports and death certificates. We used Cox proportional hazards models to determine the association of baseline adiponectin levels with 
subsequent heart failure and all-cause mortality.
Results:  During an average of 6.6 years follow-up, 22% (54/245) of patients in the highest quartile of adiponectin were hospitalized for heart 
failure vs. 13% (31/246) of patients in the lowest quartile (hazard ratio 2.00, 95% confidence interval 1.29-3.11, p=0.002). Similarly, 46% 
(113/245) of patients in the highest quartile of adiponectin died vs. 29% (72/246) of patients in the lowest quartile (hazard ratio 1.85, 95% 
confidence interval 1.38-2.48, p < 0.0001). Adjusting for traditional CAD risk factors and metabolic variables did not affect these associations. 
However, adiponectin was no longer predictive of heart failure or mortality after further adjustment for baseline measures of cardiac dysfunction.
Conclusions:  We found that higher serum concentrations of adiponectin predict heart failure and mortality among patients with existing CAD. This 
association appeared to be explained by worse baseline cardiac dysfunction in patients with higher adiponectin. These findings raise the possibility 
that adiponectin is a marker of worse cardiac disease severity among patients with existing CAD.
